EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

Chiranth K Nagaraj iD, Xilal Y Rima iD, Kim T Nguyen iD, Courtney Culkins, Nana Boateng, Jacob Doon-Ralls, Alejandro Bresolin, Xin Huang, Hong Li, Vahedi Amid, Ajeet Pal Singh, Dharti Shantaram iD und 12 weitere

Advanced Healthcare Materials · 2026-11 · 15 (41)

DOI: 10.1002/adhm.202504351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 16.07.2026. Verfasst von Chiranth K Nagaraj und 23 weiteren Autor:innen. Beteiligte Einrichtung: William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Erythrocytes, Lipids, Microfluidics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NCATS NIH HHS, National Cancer Institute, Bethesda.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A central challenge in nanomedicine is the scalable and precise engineering of nanocarriers that are simultaneously tunable, immune‐compatible, and capable of encapsulating diverse bioactive cargos. Extracellular vesicles (EVs), including native red blood cell‐derived EVs (RBCEVs), offer biocompatibility but remain limited by heterogeneous composition, low yield, poor scalability, and limited control in cargo loading. Here, we introduce a bottom‐up strategy for developing engineered red blood cell extracellular vesicles (eRBCEVs) through microfluidic diffusional mixing of purified RBC lipids and components. Parametric optimization through multi‐physics simulation enabled predictive control over flow rates, lipid concentration, and channel geometry. eRBCEVs exhibited comparable encapsulation efficiency across molecular cargos of distinct sizes and properties, including oligonucleotides, gold nanoparticles, hemoglobin, erythrocruorin (∼3.6 MDa), and full adeno‐associated virus (AAV ∼25 nm) particles, validated through cryo‐EM, chemical mapping, and high‐resolution TIRFM. Surface conjugation with CD47 peptide was established for comparison with RBCEVs; the bio‐conjugations with α‐PD‐L1 antibodies yielded functionalized vesicles with uptake in PD‐L1‐positive human tumor organoids. In vivo biodistribution and pharmacokinetic analysis in mice demonstrated sustained circulation and tissue distribution in the liver, spleen, and lungs. Neutrophil activation and macrophage uptake assays confirmed minimal immunogenicity compared to conventional particles and free‐protein controls. Collectively, our platform enables the scalable synthesis of customizable eRBCEVs that preserve RBC lipid features, support cargo flexibility, and potential for scale‐up. This work establishes eRBCEVs as a next‐generation therapeutic platform for programmable, patient‐specific delivery in gene therapy, immunomodulation, and translational nanomedicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesErythrocytesLipidsMicrofluidicsHumansAnimalsMiceNanoparticles

Stichwörter der Autor:innen

AAV‐encapsulationextracellular vesiclesmicrofluidicsnanoparticlesred blood cells

Substanzen

Lipids

Autor:innen und Institutionen

  • William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.
  • Diabetes and Metabolism Research Center, Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
  • Department of Human Sciences, Human Nutrition Program, The Ohio State University, Columbus, Ohio, USA.
  • Department of Pediatrics, Center for Clinical and Translational Research, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio, USA.
  • Jerry R. Mendell Center for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.

ORCID-Profile: Chiranth K Nagaraj, Xilal Y Rima, Kim T Nguyen, Dharti Shantaram, Anastasiia Amari, Nicholas R Merriam, Willa A Hsueh, Eduardo Reátegui

Förderung

  • NIH HHS
  • NCATS NIH HHS
  • National Cancer Institute, Bethesda
  • NHLBI NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Nagaraj, C. K., Rima, X. Y., Nguyen, K. T., Culkins, C., Boateng, N., Doon-Ralls, J., Bresolin, A., Huang, X., Li, H., Amid, V., Singh, A. P., Shantaram, D., Amari, A., Hade, M. D., Merriam, N. R., Schultz, Z. D., Harper, S. Q., Saad, N. Y., Magaña, S. M., …, & Reátegui, E. (2026). Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles. Advanced Healthcare Materials, 15(41). https://doi.org/10.1002/adhm.202504351

Vancouver

Nagaraj CK, Rima XY, Nguyen KT, Culkins C, Boateng N, Doon-Ralls J, et al. Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles. Advanced Healthcare Materials. 2026;15(41). doi:10.1002/adhm.202504351

BibTeX
@article{Nagaraj2026,
  author = {Nagaraj, Chiranth K and Rima, Xilal Y and Nguyen, Kim T and Culkins, Courtney and Boateng, Nana and Doon-Ralls, Jacob and Bresolin, Alejandro and Huang, Xin and Li, Hong and Amid, Vahedi and Singh, Ajeet Pal and Shantaram, Dharti and Amari, Anastasiia and Hade, Mangesh D and Merriam, Nicholas R and Schultz, Zachary D and Harper, Scott Q and Saad, Nizar Y and Magaña, Setty M and Hsueh, Willa A and Kopec, Rachel E and Kimmel, Blaise R and Palmer, Andre F and Reátegui, Eduardo},
  title = {Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  volume = {15},
  number = {41},
  doi = {10.1002/adhm.202504351}
}
Kostenlos starten →